These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2998675)

  • 1. Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure.
    Zanella MT; Mattei E; Draibe SA; Kater CE; Ajzen H
    Clin Pharmacol Ther; 1985 Dec; 38(6):613-7. PubMed ID: 2998675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril.
    Textor SC; Bravo EL; Fouad FM; Tarazi RC
    Am J Med; 1982 Nov; 73(5):719-25. PubMed ID: 6291388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of drug-resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, aldosterone, and electrolyte responses.
    Baer L; Radichevich I; Williams GS
    J Cardiovasc Pharmacol; 1980; 2 Suppl 2():S206-16. PubMed ID: 6156357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of angiotensin II in potassium-mediated stimulation of aldosterone secretion in the dog.
    Pratt JH
    J Clin Invest; 1982 Sep; 70(3):667-72. PubMed ID: 6286729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effect of the oral angiotensin I-converting enzyme inhibitor in long-term treatment of hypertensive patients.
    Mizuno K; Gotoh M; Matsui J; Fukuchi S
    Jpn Heart J; 1981 Nov; 22(6):903-13. PubMed ID: 7040724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trans-tubular potassium gradient in patients with drug-induced hyperkalemia.
    Mayan H; Kantor R; Farfel Z
    Nephron; 2001 Sep; 89(1):56-61. PubMed ID: 11528233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
    Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.
    Atkinson AB; Morton JJ; Brown JJ; Davies DL; Fraser R; Kelly P; Leckie B; Lever AF; Robertson JI
    Br Heart J; 1980 Sep; 44(3):290-6. PubMed ID: 7000102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.
    Giudicelli JF; Chaignon M; Richer C; Giroux B; Guedon J
    Br J Clin Pharmacol; 1984 Nov; 18(5):749-58. PubMed ID: 6095887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The treatment of severe arterial hypertension in patients with chronic kidney failure with captopril and beta-adrenoblockaders].
    Ermolenko VM; Lifshits NL; Zisel'man SB; Tatsievskiĭ VA
    Urol Nefrol (Mosk); 1991; (3):41-8. PubMed ID: 1871923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
    Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
    Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
    Ohman KP; Karlberg BE; Nilsson OR; Wettre S
    Acta Med Scand Suppl; 1981; 646():98-105. PubMed ID: 7018190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiotensin converting enzyme inhibitor on serum aldosterone and potassium level.
    Kamei H; Arakawa K
    Jpn Heart J; 1982 Mar; 23(2):191-9. PubMed ID: 7043022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients.
    Bantle JP; Nath KA; Sutherland DE; Najarian JS; Ferris TF
    Arch Intern Med; 1985 Mar; 145(3):505-8. PubMed ID: 3883934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
    McCaa RE; Gillespie JB
    Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay of various factors in glucose-induced hyperkalemia during captopril treatment.
    Radó JP; Gercsák G; Bános C
    Int J Clin Pharmacol Ther Toxicol; 1986 Feb; 24(2):69-76. PubMed ID: 3514489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.